方法对比
并排查看您选择的方法;存在差异的行会高亮显示。
| 治疗药物监测 (TDM)× | 贝叶斯推断× | |
|---|---|---|
| 领域≠ | 定量药理学 | 统计学 |
| 方法族≠ | Regression model | Bayesian methods |
| 起源年份≠ | 1988 | 1763 |
| 提出者≠ | Reynold Spector et al. | Thomas Bayes; Pierre-Simon Laplace |
| 类型≠ | Clinical measurement and dose-optimization framework | Probabilistic inference paradigm |
| 开创性文献≠ | Spector, R., Park, G. D., Johnson, G. F., & Vesell, E. S. (1988). Therapeutic drug monitoring. Clinical Pharmacology & Therapeutics, 43(4), 345–353. DOI ↗ | Bayes, T. (1763). An essay towards solving a problem in the doctrine of chances. Philosophical Transactions of the Royal Society of London, 53, 370–418. link ↗ |
| 别名≠ | Drug Level Monitoring, Serum Drug Level Monitoring, Clinical Pharmacokinetic Monitoring, İlaç Düzeyi İzlemi | Bayes inference, Bayesian statistics, Bayesian updating, posterior inference |
| 相关 | 3 | 3 |
| 摘要≠ | Therapeutic Drug Monitoring (TDM) is a clinical pharmacokinetic practice in which drug concentrations are measured in a patient's blood to guide individualized dosing. It applies principally to drugs with narrow therapeutic windows—where the margin between efficacy and toxicity is small—such as aminoglycosides, vancomycin, cyclosporine, and antiepileptics. Developed as a formal discipline in the 1980s, TDM integrates measured concentrations with pharmacokinetic modeling to calculate patient-specific dose regimens. | Bayesian inference is a statistical paradigm in which probability represents degrees of belief rather than long-run frequencies. It encodes prior knowledge about parameters in a prior distribution, combines that prior with the likelihood of observed data via Bayes' theorem, and produces a posterior distribution that quantifies updated uncertainty. The foundational theorem was published posthumously by Thomas Bayes in 1763 and subsequently systematized by Pierre-Simon Laplace in his 1812 Théorie analytique des probabilités. |
| ScholarGate数据集 ↗ |
|
|